stockrow
Friday 6 November 2026
Export CATX’s income statement to Excel — free account
Perspective Therapeutics, Inc.
CATX Healthcare Medical Devices
Perspective Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $884,000.00, down 39.2% from fiscal 2024.
- Revenue
- −72.1%
- EPS
- +24.1%
- Free cash flow
- −66.1%
- Total debt
- −3.57%
Quarter to June 2026, against a year earlier
0.84
0.05
+6.33%
Follow CATX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 3 | 2 |
+8 more TTM periods Free account |
| (39.50%) | (35.16%) | (41.44%) | (37.08%) | ||
| (33.14%) | (30.03%) | (33.92%) | (30.85%) | ||
ROIC |
(88.41%) | (96.09%) | (111.14%) | (106.51%) | |
Return on Tangible Assets |
(37.23%) | (33.04%) | (52.53%) | (47.61%) | |
Average Days of Receivables |
240.06 | 34.26 | 2.48 | 60.78 | |
Free Cash Flow per Share |
(1.00) | (1.04) | (1.29) | (1.43) | |
Free Cash Flow |
(121.19) | (107.32) | (95.23) | (106.39) | |
Capital Expenditures |
(28.12) | (14.95) | (12.75) | (21.95) | |
| Other line items | |||||
Cash ROIC |
(21.55%) | (17.31%) | (26.95%) | (25.46%) | |
Accounts Receivable Turnover |
1.66 | 9.09 | 14.49 | 5.43 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
23,515.65% | 14,766.18% | 9,526.58% | 5,969.67% | |
Selling, General and Administrative Expense of Revenue |
7,203.42% | 4,753.40% | 3,420.02% | 2,932.84% | |
Share Based Compensation of Revenue |
2,460.64% | 1,524.43% | 1,014.25% | 810.88% | |
Interest Coverage |
(410.60) | (339.98) | (302.03) | (496.72) | |
Operating CF/Net income |
0.80 | 0.83 | 0.80 | 0.80 | |
Depreciation/Fixed assets |
0.02 | 0.02 | 0.01 | 0.37 | |
Capex/Depreciation |
(14.46) | (10.51) | (24.15) | (0.91) | |
Revenue per Share |
0.00 | 0.01 | 0.01 | 0.01 | |
Operating CF per Share |
(0.77) | (0.89) | (1.12) | (1.14) | |
Capex per Share |
(0.23) | (0.14) | (0.17) | (0.30) | |
Capex to Sales |
68.75 | 24.19 | 14.42 | 20.42 |
Columns are period end dates · fundamentals updated 26 Oct 2026